Minerva Neurosciences (NERV) Change in Cash (2013 - 2026)
Minerva Neurosciences (NERV) posted Change in Cash of -$49.6 million for Q1 2026, down 170.9% on a QoQ basis from $70.0 million in Q4 2025, and down 1119.12% year-over-year from $4.9 million in Q1 2025.
Minerva Neurosciences (NERV) Change in Cash (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Change in Cash history runs 14 years deep, the most recent figure standing at -$49.6 million for Q1 2026.
- Quarterly Change in Cash fell 1119.12% year-over-year to -$49.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.4 million (up 187.69% YoY) and the FY2025 annual result came in at $60.9 million, up 411.7% from the prior year.
- Change in Cash was -$49.6 million for Q1 2026 at Minerva Neurosciences, down from $70.0 million in the prior quarter.
- Across five years, Change in Cash topped out at $70.0 million in Q4 2025 and bottomed at -$49.6 million in Q1 2026.
- A 5-year average of -$1.7 million and a median of -$4.4 million in 2024 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2024 — Change in Cash sank 5180.68% — and 2025, when it soared 1455.1%.
- Minerva Neurosciences' Change in Cash stood at -$4.1 million in 2022, then sank by 45.2% to -$6.0 million in 2023, then rose by 13.76% to -$5.2 million in 2024, then surged by 1455.1% to $70.0 million in 2025, then slumped by 170.9% to -$49.6 million in 2026.
- Business Quant data shows NERV's Change in Cash at -$49.6 million in Q1 2026, $70.0 million in Q4 2025, and -$3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -22.03 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 243.78 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 417.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -153.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | -49.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.64 Mn |
| Dec 31, 2025 | 70.02 Mn |
| Sep 30, 2025 | -2.96 Mn |
| Jun 30, 2025 | -2.04 Mn |
| Mar 31, 2025 | -4.07 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Sep 30, 2024 | -4.35 Mn |
| Jun 30, 2024 | -3.94 Mn |
| Mar 31, 2024 | -6.09 Mn |
| Dec 31, 2023 | -5.99 Mn |
| Sep 30, 2023 | -4.89 Mn |
| Jun 30, 2023 | 15.82 Mn |
| Mar 31, 2023 | -115,407.00 |
| Dec 31, 2022 | -4.13 Mn |
| Sep 30, 2022 | -9.53 Mn |
| Jun 30, 2022 | -5.19 Mn |
| Mar 31, 2022 | -5.81 Mn |
| Dec 31, 2021 | -4.83 Mn |
| Sep 30, 2021 | -8.63 Mn |
| Jun 30, 2021 | -5.92 Mn |